Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Brief Summary: This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on metformin monotherapy. The primay hypothesis of the study is that after 54 weeks, the mean change from baseline in hemoglobin A1C (A1C) in participants treated with omarigliptin is non-inferior compared with that in participants treated with glimepiride.


Options:
A: Arm Label: Omarigliptin; Type: EXPERIMENTAL; Interventions: Drug: Omarigliptin, Drug: Glimepiride Placebo, Drug: Metformin, Drug: Insulin Glargine | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to Omarigliptin, Drug: Glimepiride, Drug: Metformin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: Omarigliptin; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Placebo to Omarigliptin; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Glimepiride Placebo; Assigned to Arm(s): Omarigliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glimepiride, Omarigliptin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Glimepiride, Omarigliptin
B: Arm Label: Saxagliptin and Metformin (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Metformin (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin, Drug: pioglitazone | Arm Label: Saxagliptin and Placebo (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo, Drug: pioglitazone | Arm Label: Metformin and Placebo (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Placebo, Drug: pioglitazone | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (A), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Placebo (C) | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Metformin and Placebo (D), Saxagliptin and Metformin (A), Saxagliptin and Metformin (B), Saxagliptin and Placebo (C)
C: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride

Answer: A